LLY
Lilly’s latest flex
Eli Lilly is back with another obesity-data victory lap, and this one has a very specific audience: women navigating menopause. On Sunday, the company presented new post-hoc analyses at the American Diabetes Association’s 86th Scientific Sessions showing that Foundayo produced significant weight loss across all menopause stages.
The headline is simple enough: the drug didn’t suddenly get stage fright just because hormones entered the chat. In both ATTAIN-1 and ATTAIN-2, women on the highest dose saw meaningful reductions over 72 weeks whether they were pre-, peri-, or post-menopausal.
The numbers that matter
This wasn’t a tiny, cherry-picked corner of the dataset either. Lilly says the analysis covered more than 1,500 women across the two trials. Among them:
- In ATTAIN-1, participants lost up to 28.0 pounds before menopause, 30.4 pounds during the transition, and 28.2 pounds after menopause.
- In ATTAIN-2, which included women with type 2 diabetes, weight loss reached up to 23.4 pounds, 18.5 pounds, and 27.8 pounds across the same groups.
- At the top dose, as many as 51.5% of women in ATTAIN-1 and 44.2% in ATTAIN-2 hit at least 15% weight loss.
- Waist circumference dropped too, by as much as 4.9 inches in ATTAIN-1 and 4.3 inches in ATTAIN-2.
That’s the kind of data that makes investors perk up, because obesity drugs aren’t just a one-trial story anymore. They’re turning into a portfolio, a category, and basically a whole corporate personality.
Why Wall Street cares
The market loves a good “this works in a new subgroup” story, especially when the drug sits in one of pharma’s hottest races. More clinical support can help Lilly expand the commercial moat around its weight-loss franchise, even as competitors keep trying to crash the party.
And the stock noticed. Shares were up 2.10% on Monday and were flirting with their 52-week high. When a company is already expensive, it doesn’t need miracles — it needs proof that the growth runway is still long and the scissors aren’t coming for the narrative.
Big picture: Lilly keeps adding more tiles to the same mosaic, and the picture is looking a lot like “obesity leadership, with bonus pipeline swagger.”